Beam Therapeutics Inc. (BEAM) Stock

Beam Therapeutics Inc., a pioneering biotechnology company headquartered in Cambridge, Massachusetts, is dedicated to advancing precision genetic medicines to treat severe diseases across the United States. The company's innovative pipeline includes BEAM-101 and BEAM-102, targeted therapies under development for sickle cell disease and beta thalassemia. Additionally, Beam Therapeutics is progressing BEAM-201, an allogeneic chimeric antigen receptor T cell therapy designed to address relapsed/refractory T-cell acute lymphoblastic leukemia, and BEAM-301, a liver-targeted candidate for Glycogen Storage Disease Type Ia.

Beyond these efforts, Beam Therapeutics is actively developing therapies for a spectrum of conditions including alpha-1 antitrypsin deficiency, ocular diseases, and disorders affecting the liver, muscle, and central nervous system. The company operates through strategic alliances and collaborations, exemplified by partnerships with Boston Children's Hospital, Magenta Therapeutics, Inc., Sana Biotechnology, Inc., the Institute of Molecular and Clinical Ophthalmology Basel, Pfizer Inc., Apellis Pharmaceuticals, Inc., and Verve Therapeutics, Inc.

Founded in 2017, Beam Therapeutics has rapidly established itself as a leader in precision genetic medicine, leveraging cutting-edge CRISPR technology to develop transformative therapies. The company's collaborative approach to research and development fosters innovation and accelerates the translation of scientific discoveries into therapeutic solutions that address significant unmet medical needs.

Headquartered in the vibrant biotechnology hub of Cambridge, Massachusetts, Beam Therapeutics benefits from proximity to world-class research institutions and a thriving biotech ecosystem. With a commitment to pioneering new standards of care, Beam Therapeutics continues to push the boundaries of genetic medicine, aiming to improve outcomes and quality of life for patients worldwide.